The Trump administration broadened its voluntary Most Favored Nation pricing initiative by securing agreements with nine more drugmakers, bringing total participation to 26 pharmaceutical manufacturers. The White House fact sheet states that these 26 agreements cover 89 percent of the branded drug market.
Under these agreements, companies will offer undisclosed Medicaid discounts aimed at aligning certain U.S. drug prices more closely with lower international prices. However, industry observers note that these deals may exempt participating manufacturers from forthcoming Medicare drug pricing pilot programs, potentially leaving smaller and midsize companies to bear the impact of mandatory pricing reforms. As a result, questions are emerging about the overall savings potential, legal viability, and long-term effectiveness of the administration’s broader drug pricing strategy, particularly if major manufacturers are excluded from future models intended to lower Medicare spending.
Read more here.
